<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928447</url>
  </required_header>
  <id_info>
    <org_study_id>HALO-114-201</org_study_id>
    <nct_id>NCT00928447</nct_id>
  </id_info>
  <brief_title>Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halozyme Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the&#xD;
      treatment of skin allergic reaction to nickel. The study drug and placebo will be&#xD;
      administered by intradermal injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot Phase II, prospective, double-blind, placebo-controlled study to compare the&#xD;
      efficacy, safety and tolerability of rHuPH20 or placebo control administered intradermally&#xD;
      (ID) in the prevention and treatment of subjects with contact allergy to nickel. This study&#xD;
      will involve two treatment regimens, which will run in parallel (Treatment Regimens 1 and 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the treatment effect of rHuPH20 or placebo control injection on the exposure to topical nickel allergen</measure>
    <time_frame>7-14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the time to onset and severity of the cutaneous reaction to nickel allergen after pre-treatment with rHuPH20 or placebo control</measure>
    <time_frame>7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of the rHuPH20 injection</measure>
    <time_frame>7-14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Dermatitis, Allergic Contact</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment effect of rHuPH20 injection on the exposure to topical nickel allergen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment effect of placebo control injection on the exposure to topical nickel allergen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuPH20</intervention_name>
    <description>ID syringe push bolus injection of rHuPH20. Each injection will be administered once daily for 5 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ID syringe push bolus injection of placebo control. Each injection will be administered once daily for 5 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females 18-60 years of age. Females of child-bearing potential must use a standard and&#xD;
             effective means of birth control for the duration of the study.&#xD;
&#xD;
          -  Known contact dermatitis to nickel with a confirmed positive patch-test result to&#xD;
             nickel sulfate.&#xD;
&#xD;
          -  Intact normal skin without potentially obscuring tattoos, acne, dermatitis,&#xD;
             pigmentation or lesions on the posterior aspect of the torso (back) in the area&#xD;
             intended for allergen testing and dose administration.&#xD;
&#xD;
          -  Vital signs (BP, HR, temperature, respiratory rate) within normal range or, if out of&#xD;
             range, assessed by the Investigator as not clinically significant and it is mutually&#xD;
             agreed by both Investigator and Sponsor Medical Monitor that the subject need not be&#xD;
             excluded from the study for this reason.&#xD;
&#xD;
          -  A negative serum or urine pregnancy test (if female of child-bearing potential) within&#xD;
             14 days of initial study drug administration.&#xD;
&#xD;
          -  Subject should be in good general health based on medical history and physical&#xD;
             examination, without medical conditions that might prevent the completion of study&#xD;
             drug injections and assessments required in this protocol.&#xD;
&#xD;
          -  Decision-making capacity and willingness and ability to comply with the requirements&#xD;
             for full completion of the study.&#xD;
&#xD;
          -  Signed, written Institutional Review Board (IRB)/EC-approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nickel allergen patch test greater than a ++ reaction.&#xD;
&#xD;
          -  Subjects who were treated with chemotherapy agents or systemic corticosteroids within&#xD;
             the past 3 months.&#xD;
&#xD;
          -  Use of topical steroids, antihistamines, or immunosuppressants used near the site of&#xD;
             allergen testing/injection within 14 days.&#xD;
&#xD;
          -  Use of oral antihistamines within 14 days of study conduct.&#xD;
&#xD;
          -  Extensive ongoing outbreaks of contact dermatitis anywhere on the body.&#xD;
&#xD;
          -  Pregnant or women who are breast-feeding.&#xD;
&#xD;
          -  Subjects with a current disease state that can affect immune response (e.g., flu,&#xD;
             cancer, HIV).&#xD;
&#xD;
          -  Known allergy to any hyaluronidase or the ingredients in the dose preparation.&#xD;
&#xD;
          -  History of autoimmune disorder.&#xD;
&#xD;
          -  Subjects with any other medical condition that, in the opinion of the investigator,&#xD;
             might significantly affect their ability to safely participate in the study or affect&#xD;
             the conduct of this study. Examples might include asthma, diabetes, heart disease,&#xD;
             epilepsy, cancer, etc.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikeadi M Ndukwu, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Anthony Memorial Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Symbio Phase I Unit, Saint Anthony Memorial Research Center</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <disposition_first_submitted>June 28, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 28, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 3, 2018</disposition_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rHuPH20</keyword>
  <keyword>Recombinant Human hyaluronidase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
    <mesh_term>Dermatitis, Allergic Contact</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 8, 2021</submitted>
    <returned>September 30, 2021</returned>
    <submitted>October 21, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

